公开(公告)号：US20210101891A1

公开(公告)日：2021-04-08

申请号：US17075206

申请日：2020-10-20

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU INSTITUTE OF DRUG INNOVATION, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENC

发明人： Bing Zhou ,  Cheng Luo ,  Hualiang Jiang ,  Yaxi Yang ,  Lianghe Mei ,  Wenchao Lu ,  Senhao Xiao ,  Shijie Chen ,  Shili Wan ,  Gang Qiao ,  Rukang Zhang

IPC分类号： C07D413/06 ,  C07D417/06 ,  C07D413/14 ,  C07D491/107 ,  C07D513/04 ,  C07D471/04 ,  C07D495/04 ,  C07D495/10

摘要： Disclosed is a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by the general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereoisomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising same and use thereof in the treatment of various HAT-related diseases or conditions.

公开(公告)号：US20220002278A9

公开(公告)日：2022-01-06

申请号：US17075206

申请日：2020-10-20

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU INSTITUTE OF DRUG INNOVATION, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Bing Zhou ,  Cheng Luo ,  Hualiang Jiang ,  Yaxi Yang ,  Lianghe Mei ,  Wenchao Lu ,  Senhao Xiao ,  Shijie Chen ,  Shili Wan ,  Gang Qiao ,  Rukang Zhang

IPC分类号： C07D413/06 ,  C07D417/06 ,  C07D413/14 ,  C07D491/107 ,  C07D513/04 ,  C07D471/04 ,  C07D495/04 ,  C07D495/10

摘要： Disclosed is a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by the general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereoisomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising same and use thereof in the treatment of various HAT-related diseases or conditions.

公开(公告)号：US11427593B2

公开(公告)日：2022-08-30

申请号：US16962347

申请日：2019-01-11

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU SUPLEAD LIFE SCIENCES CO., LTD.

发明人： Bing Zhou ,  Cheng Luo ,  Zizhou Li ,  Yaxi Yang ,  Shijie Chen ,  Hong Ding ,  Hualiang Jiang ,  Gang Qiao ,  Xinjun Wang ,  Senhao Xiao

IPC分类号： C07D487/04 ,  A61P35/00 ,  A61P35/02

摘要： The present invention relates to a bromodomain inhibitor. Provided are a compound represented by general formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, atropisomer, racemate, polymorph, solvate, or isotopically labeled compound (including deuterium substitution) thereof, a preparation method of the same, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof.

公开(公告)号：US11013745B2

公开(公告)日：2021-05-25

申请号：US16651510

申请日：2018-08-29

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU SUPLEAD LIFE SCIENCES CO., LTD.

发明人： Bing Zhou ,  Cheng Luo ,  Yaxi Yang ,  Yuanyuan Zhang ,  Daohai Du ,  Hualiang Jiang ,  Gang Qiao ,  Xinjun Wang

IPC分类号： A61K31/519 ,  C07D487/04

摘要： The present invention provides a compound represented by formula I, pharmaceutically acceptable salts, enantiomers, diastereomers or racemates thereof, the preparation method thereof, the pharmaceutical composition comprising the same, and the use thereof in the preparation of a medicament for treating a disease or condition mediated by EED and/or PRC2. The compound of the present invention can be used treating PRC2-mediated diseases or conditions.